1. Home
  2. DSL vs DMRA Comparison

DSL vs DMRA Comparison

Compare DSL & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DoubleLine Income Solutions Fund of Beneficial Interests

DSL

DoubleLine Income Solutions Fund of Beneficial Interests

HOLD

Current Price

$10.89

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$21.24

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DSL
DMRA
Founded
2013
2011
Country
United States
United States
Employees
N/A
7
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.5B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
DSL
DMRA
Price
$10.89
$21.24
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$43.00
AVG Volume (30 Days)
454.6K
308.6K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
11.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.49
$16.50
52 Week High
$12.67
$28.76

Technical Indicators

Market Signals
Indicator
DSL
DMRA
Relative Strength Index (RSI) 46.76 37.24
Support Level $10.55 N/A
Resistance Level $11.19 $27.70
Average True Range (ATR) 0.10 1.89
MACD -0.01 -0.37
Stochastic Oscillator 32.88 32.95

Price Performance

Historical Comparison
DSL
DMRA

About DSL DoubleLine Income Solutions Fund of Beneficial Interests

DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: